Cygnus Biosciences (Beijing) Co., Ltd. (hereinafter referred to as “Cygnus Biosciences” or “the Company”) is a national high-tech enterprise integrating R&D, conversion, production, and marketing of gene sequencing technology. Founded by Academician Xie Xiaoliang, Professor Huang Yanyi, Dr. Chen Zitian's team, The Company specializes in the research, development, manufacturing, and marketing of gene sequencing instruments, reagents, consumables, and gene testing services. Cygnus is dedicated to providing simpler, more accurate, and efficient gene sequencing tools and solutions for various fields in the life sciences, including biological research, medical diagnosis, drug development, animal and plant breeding, customs, disease control, forensic science, and evolutionary research.
As a leading enterprise in original research for Sequencing System, Cygnus Biosciences has consistently viewed innovation as the driving force behind its development. The company currently holds foundational core patent technologies in sequencing, including Fluorogenic sequencing chemistry, Error-correction code (ECC) sequencing, LumoSeq, and AttoSeal. Cygnus possesses original foundational gene sequencing technology and fully independent intellectual property rights in high-throughput gene sequencing technology. Currently, the company has filed nearly 200 domestic and international patents, achieving comprehensive coverage for patents related toequipment, reagents, chips, and algorithms. Cygnus has launched the GS100 Sequencing System、the GP1000 Sequencing System and the GP1000X Sequencing System.